CDK4 and bone metastasis: In our study, the RANKL inhibitor denosumab, used in conjunction with CDK4/6 inhibitors, was observed to delay SREs following bone metastasis and have a lower SRE incidence compared to zoledronic acid; this result suggests a clinical manifestation of the aforementioned mechanisms.